Abstract
Oral teneligliptin [Teneglucon® (Argentina)], a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, is a useful option to improve glycaemic control in patients with type 2 diabetes who have not responded adequately to treatment with diet and exercise, or the addition of biguanides, sulfonylureas or thiazolidinediones. In clinical trials, teneligliptin (20 or 40 mg once daily) monotherapy or combination therapy with metformin, glimepiride or pioglitazone, improved glycaemic control, including in patients with end-stage renal disease receiving haemodialysis. Improvements in glycaemic control were sustained after 52 weeks’ treatment. Teneligliptin is generally well tolerated, does not increase the risk of hypoglycaemia and is bodyweight neutral.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
